Case Study

AMAG Pharmaceuticals

Soliant Sheds Light on the Physician Payments Sunshine Act

When Congress passed the Affordable Care Act, it included a provision, commonly known as the Physician Payments Sunshine Act, which requires pharmaceutical companies to report payments made to physicians, manufacturers, and teaching hospitals, creating greater transparency around their financial relationships.

AMAG Pharmaceuticals, a rapidly growing specialty pharmaceutical company, faced a steep challenge, like many other pharmaceutical companies: how to effectively gather and aggregate the data representing these payments from disparate data sources in order to meet the 2014 report deadline.

Quote mark
Nate McBride

Vice President, IT

Soliant’s work has not only allowed us to comply with the new regulation, but will save us at least $100k annually. Soliant’s team did an amazing job of making the complex seem simple.

AMAG needed to collect and report data distributed across eleven different sources such as their CRM (customer relationship management) system, speaker expense system, accounts payable system, CRO (contract research organization) system, and travel and expense management system. After considering an off-the-shelf packaged system in the multiple six-figure price range, Nate McBride, AMAG’s Vice President of IT, turned to Soliant for a custom, more cost-effective solution.Soliant’s team did an amazing job of making the complex seem simple.

Soliant partnered with AMAG to deliver a FileMaker Pro system that imports, cleans, and aggregates data into a single reporting source, which allows AMAG to satisfy all applicable regulations. Soliant developed the FileMaker Pro solution at 15% of the cost less than the expensive, generic software alternative.

AMAG Pharmaceuticals logo

 About AMAG Pharmaceuticals

AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products. AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company’s commercial footprint and focus on hematology and oncology centers and hospital infusion centers.